"Advancements in Bluebird Gene Therapies, Vertex's Pain Drug, and ADC FOMO"

Bluebird Bio's focus on selling gene therapies, such as Lyfgenia for sickle cell disease, Zynteglo for beta thalassemia, and Skysona for cerebral adrenoleukodystrophy, without other marketed products, makes it a unique player in the gene therapy market, raising questions about the profitability of gene therapies as a business. The company's approach and success over the next year may provide insights into the potential for gene therapies to become a profitable venture.